News Releases

News and information from The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society Launches National Patient Registry to Answer Crucial COVID-19 Questions for Blood Cancer Patients

RYE BROOK, N.Y., Feb. 17, 2021 – The Leukemia & Lymphoma Society (LLS) announced today a collaboration with Ciitizen, a digital health technology startup, to collect data on the impact of COVID-19 and vaccination from people with a current or past diagnosis of blood cancer as part of a broader strategic partnership. The LLS National Patient Registry opened today to enroll all blood cancer patients, including th...

NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

Rye Brook, N.Y. (February 26, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of melphalan flufenamide, also known as melflufen (Pepaxto), in combination with dexamethasone for the treatment of adults with multiple myeloma whose disease has returned or worsened following prior treatment with four different classes of drugs. Today’s approval of melflufen was based on results fr...

The Leukemia & Lymphoma Society Joins CURE Media Group's Strategic Alliance Partnership Program

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and caregivers, announces the addition of The Leukemia & Lymphoma Society (LLS) to its Strategic Alliance Partnership (SAP) program. “We are proud to be working with LLS and supporting them in their mission to support those affected by all blood canc...

Burlington Stores & its Customers Raise Nearly $4 Million for The Leukemia & Lymphoma Society (LLS) in the Fight Against Blood Cancer

RYE BROOK, NY, February 10, 2021  – The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to further their LLS Children’s Init...

Patient organizations applaud strong actions to protect people with pre-existing conditions

WASHINGTON, D.C. – Thirty-three organizations representing millions of people with pre-existing conditions applaud the much-needed patient protections in two Executive Orders issued by President Biden on January 28. The organizations released the following statement: “President Biden’s actions this week represent a significant first step towards improving access to high-quality health coverage for people ...

NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH RARE MARGINAL ZONE LYMPHOMA AND ADVANCED FOLLICULAR LYMPHOMA

Rye Brook, N.Y. (February 5, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody. MZL is a clinical heterogeneous, slow-growing non-hodgkin lymphoma composed of three subtypes: extranodal, nodal or splen...

LLS Statement on Inauguration Day 2021

Our right to vote is the heart of our democracy, as is a free and fair election. The democratic process is critical to our work at The Leukemia & Lymphoma Society where civic engagement is a cornerstone of our values. Every day, LLS works directly with lawmakers at the state and federal levels to advance policies that serve the best interests of blood cancer patients. Every member of the LLS community – staff, ...

FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder

Rye Brook, N.Y. (January 19, 2021) – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (C...

Pages

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.